Study Name: A non-interventional study of HLA-DRB1*04:01 distribution in adults with recently diagnosed type 1 diabetes (T1D)
Principal Investigator: Brittany Bruggeman, M.D.
What is the GentiBio HLA study?
The purpose of this study is to learn how many people with T1D have a particular type of gene, called HLA-DRB1*04:01. Some prior research suggests people with certain HLA genes are more likely to develop T1D.
If you participate in this research study and are positive for this gene, you may be eligible to participate in the main GentiBio study.
Who can participate?
- Participants who are between 18 and 45 years old
- Have recently been diagnosed with T1D (enrolled in study within 120 days of type 1 diabetes diagnosis)
What does participation in GentiBio HLA look like
The GentiBio HLA study will include approximately 50 participants. The study visit will be approximately 1 hour long and will include going over the consent form, recording demographic and medical information, and a blood draw. There is a possibility to conduct the study visit remotely for participants who do not live near UF.
Want to learn more?
Call (352) 294-5760 or email our Study Coordinators: